Gene · 10666
Papers4,079
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 4,079
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Modifiable lifestyle factors influencing psychiatric disorders mediated by plasma proteins: A systemic Mendelian randomization study. | J Affect Disord | 2024 | 38246286 | PubTator, text mining | PubMed |
| Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer. | NPJ Precis Oncol | 2024 | 38245587 | PubTator, text mining | PubMed |
| Breakthrough of solid tumor treatment: CAR-NK immunotherapy. | Cell Death Discov | 2024 | 38245520 | PubTator, text mining | PubMed |
| Blocking CD226 regulates type 2 innate lymphoid cell effector function and alleviates airway hyperreactivity. | J Allergy Clin Immunol | 2024 | 38244725 | PubTator, text mining | PubMed |
| Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases. | Cancer Immunol Immunother | 2024 | 38231291 | PubTator, text mining | PubMed |
| Targeting TIGIT for cancer immunotherapy: recent advances and future directions. | Biomark Res | 2024 | 38229100 | PubTator, text mining | PubMed |
| Advances in the research on myokine-driven regulation of bone metabolism. | Heliyon | 2024 | 38226270 | PubTator, text mining | PubMed |
| In-depth analysis of prognostic markers associated with the tumor immune microenvironment and genetic mutations in breast cancer based on an NK cell-related risk model. | Heliyon | 2024 | 38226219 | PubTator, text mining | PubMed |
| Harnessing natural killer cell effector function against cancer. | Immunother Adv | 2024 | 38223411 | PubTator, text mining | PubMed |
| Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside. | Cell Death Dis | 2024 | 38221520 | PubTator, text mining | PubMed |
| The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling. | Cell Commun Signal | 2024 | 38216949 | PubTator, text mining | PubMed |
| Unraveling the dynamic mechanisms of natural killer cells in viral infections: insights and implications. | Virol J | 2024 | 38216935 | PubTator, text mining | PubMed |
| The Plasticity of Immune Cell Response Complicates Dissecting the Underlying Pathology of Multiple Sclerosis. | J Immunol Res | 2024 | 38213874 | PubTator, text mining | PubMed |
| Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. | Cell | 2024 | 38211590 | PubTator, text mining | PubMed |
| CD47 overexpression is related to tumour-associated macrophage infiltration and diffuse large B-cell lymphoma progression. | Clin Transl Med | 2024 | 38193627 | PubTator, text mining | PubMed |
| Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS. | Blood Adv | 2024 | 38191686 | PubTator, text mining | PubMed |
| Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma. | J Immunother Cancer | 2024 | 38191242 | PubTator, text mining | PubMed |
| The chemokine receptor CXCR3 promotes CD8+ T cell-dependent lung pathology during influenza pathogenesis. | Sci Adv | 2024 | 38170765 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing reveals that the immunosuppression landscape induced by chronic stress promotes colorectal cancer metastasis. | Heliyon | 2024 | 38169984 | PubTator, text mining | PubMed |
| PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma. | Oncoimmunology | 2024 | 38125723 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10666/papers?page=15